胆管がん用治療薬の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21JNE3618)
◆英語タイトル:Global Bile Duct Cancer Therapeutics Market Size, Status and Forecast 2021-2027
◆商品コード:QY21JNE3618
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年6月(※2024年版があります。お問い合わせください。)
◆ページ数:108
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、胆管がん用治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(医薬品、手術、その他)、用途別市場規模(病院、診療所、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・胆管がん用治療薬の市場動向
・企業の競争状況、市場シェア
・胆管がん用治療薬の種類別市場規模(医薬品、手術、その他)
・胆管がん用治療薬の用途別市場規模(病院、診療所、その他)
・胆管がん用治療薬の北米市場規模2016-2027(アメリカ、カナダ)
・胆管がん用治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・胆管がん用治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・胆管がん用治療薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・胆管がん用治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Pfizer、F. Hoffmann-La Roche、Bristol-Myers Squibb、Teva Pharmaceutical、Eli Lilly and Company、Sanofi、Fresenius Kabi、Mylan、Delcath Systems、Accord Healthcare、Intercept Pharmaceuticals、Celgene)
・結論
【レポートの概要】

Bile Duct Cancer is a rare type of cancer that mainly affects adults aged over 65. Bile ducts are small tubes that connect the liver and small intestine that allow fluid called bile to flow from the liver, through the pancreas, to the gut, where it helps with digestion.

Market Analysis and Insights: Global Bile Duct Cancer Therapeutics Market
The global Bile Duct Cancer Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Bile Duct Cancer Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Bile Duct Cancer Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Bile Duct Cancer Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Bile Duct Cancer Therapeutics market.

Global Bile Duct Cancer Therapeutics Scope and Market Size
Bile Duct Cancer Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Bile Duct Cancer Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Mecine
Surgery
Other

Segment by Application
Hospitals
Clinics
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Pfizer
F. Hoffmann-La Roche
Bristol-Myers Squibb
Teva Pharmaceutical
Eli Lilly and Company
Sanofi
Fresenius Kabi
Mylan
Delcath Systems
Accord Healthcare
Intercept Pharmaceuticals
Celgene

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bile Duct Cancer Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Mecine
1.2.3 Surgery
1.2.4 Other
1.3 Market by Application
1.3.1 Global Bile Duct Cancer Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Bile Duct Cancer Therapeutics Market Perspective (2016-2027)
2.2 Bile Duct Cancer Therapeutics Growth Trends by Regions
2.2.1 Bile Duct Cancer Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Bile Duct Cancer Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Bile Duct Cancer Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Bile Duct Cancer Therapeutics Industry Dynamic
2.3.1 Bile Duct Cancer Therapeutics Market Trends
2.3.2 Bile Duct Cancer Therapeutics Market Drivers
2.3.3 Bile Duct Cancer Therapeutics Market Challenges
2.3.4 Bile Duct Cancer Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Bile Duct Cancer Therapeutics Players by Revenue
3.1.1 Global Top Bile Duct Cancer Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Bile Duct Cancer Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Bile Duct Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Bile Duct Cancer Therapeutics Revenue
3.4 Global Bile Duct Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Bile Duct Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bile Duct Cancer Therapeutics Revenue in 2020
3.5 Bile Duct Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Bile Duct Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Bile Duct Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Bile Duct Cancer Therapeutics Breakdown Data by Type
4.1 Global Bile Duct Cancer Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Bile Duct Cancer Therapeutics Forecasted Market Size by Type (2022-2027)

5 Bile Duct Cancer Therapeutics Breakdown Data by Application
5.1 Global Bile Duct Cancer Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Bile Duct Cancer Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Bile Duct Cancer Therapeutics Market Size (2016-2027)
6.2 North America Bile Duct Cancer Therapeutics Market Size by Type
6.2.1 North America Bile Duct Cancer Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Bile Duct Cancer Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Bile Duct Cancer Therapeutics Market Size by Type (2016-2027)
6.3 North America Bile Duct Cancer Therapeutics Market Size by Application
6.3.1 North America Bile Duct Cancer Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Bile Duct Cancer Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Bile Duct Cancer Therapeutics Market Size by Application (2016-2027)
6.4 North America Bile Duct Cancer Therapeutics Market Size by Country
6.4.1 North America Bile Duct Cancer Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Bile Duct Cancer Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Bile Duct Cancer Therapeutics Market Size (2016-2027)
7.2 Europe Bile Duct Cancer Therapeutics Market Size by Type
7.2.1 Europe Bile Duct Cancer Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Bile Duct Cancer Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Bile Duct Cancer Therapeutics Market Size by Type (2016-2027)
7.3 Europe Bile Duct Cancer Therapeutics Market Size by Application
7.3.1 Europe Bile Duct Cancer Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Bile Duct Cancer Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Bile Duct Cancer Therapeutics Market Size by Application (2016-2027)
7.4 Europe Bile Duct Cancer Therapeutics Market Size by Country
7.4.1 Europe Bile Duct Cancer Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Bile Duct Cancer Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Bile Duct Cancer Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Type
8.2.1 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Application
8.3.1 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Region
8.4.1 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Bile Duct Cancer Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Bile Duct Cancer Therapeutics Market Size (2016-2027)
9.2 Latin America Bile Duct Cancer Therapeutics Market Size by Type
9.2.1 Latin America Bile Duct Cancer Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Bile Duct Cancer Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Bile Duct Cancer Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Bile Duct Cancer Therapeutics Market Size by Application
9.3.1 Latin America Bile Duct Cancer Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Bile Duct Cancer Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Bile Duct Cancer Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Bile Duct Cancer Therapeutics Market Size by Country
9.4.1 Latin America Bile Duct Cancer Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Bile Duct Cancer Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Bile Duct Cancer Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Type
10.2.1 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Application
10.3.1 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Country
10.4.1 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Bile Duct Cancer Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Bile Duct Cancer Therapeutics Introduction
11.1.4 Pfizer Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Company Details
11.2.2 F. Hoffmann-La Roche Business Overview
11.2.3 F. Hoffmann-La Roche Bile Duct Cancer Therapeutics Introduction
11.2.4 F. Hoffmann-La Roche Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.2.5 F. Hoffmann-La Roche Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Bile Duct Cancer Therapeutics Introduction
11.3.4 Bristol-Myers Squibb Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Teva Pharmaceutical
11.4.1 Teva Pharmaceutical Company Details
11.4.2 Teva Pharmaceutical Business Overview
11.4.3 Teva Pharmaceutical Bile Duct Cancer Therapeutics Introduction
11.4.4 Teva Pharmaceutical Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.4.5 Teva Pharmaceutical Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Bile Duct Cancer Therapeutics Introduction
11.5.4 Eli Lilly and Company Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.5.5 Eli Lilly and Company Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Details
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Bile Duct Cancer Therapeutics Introduction
11.6.4 Sanofi Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.6.5 Sanofi Recent Development
11.7 Fresenius Kabi
11.7.1 Fresenius Kabi Company Details
11.7.2 Fresenius Kabi Business Overview
11.7.3 Fresenius Kabi Bile Duct Cancer Therapeutics Introduction
11.7.4 Fresenius Kabi Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.7.5 Fresenius Kabi Recent Development
11.8 Mylan
11.8.1 Mylan Company Details
11.8.2 Mylan Business Overview
11.8.3 Mylan Bile Duct Cancer Therapeutics Introduction
11.8.4 Mylan Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.8.5 Mylan Recent Development
11.9 Delcath Systems
11.9.1 Delcath Systems Company Details
11.9.2 Delcath Systems Business Overview
11.9.3 Delcath Systems Bile Duct Cancer Therapeutics Introduction
11.9.4 Delcath Systems Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.9.5 Delcath Systems Recent Development
11.10 Accord Healthcare
11.10.1 Accord Healthcare Company Details
11.10.2 Accord Healthcare Business Overview
11.10.3 Accord Healthcare Bile Duct Cancer Therapeutics Introduction
11.10.4 Accord Healthcare Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.10.5 Accord Healthcare Recent Development
11.11 Intercept Pharmaceuticals
11.11.1 Intercept Pharmaceuticals Company Details
11.11.2 Intercept Pharmaceuticals Business Overview
11.11.3 Intercept Pharmaceuticals Bile Duct Cancer Therapeutics Introduction
11.11.4 Intercept Pharmaceuticals Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.11.5 Intercept Pharmaceuticals Recent Development
11.12 Celgene
11.12.1 Celgene Company Details
11.12.2 Celgene Business Overview
11.12.3 Celgene Bile Duct Cancer Therapeutics Introduction
11.12.4 Celgene Revenue in Bile Duct Cancer Therapeutics Business (2016-2021)
11.12.5 Celgene Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 胆管がん用治療薬の世界市場規模・現状・予測2021年-2027年(Global Bile Duct Cancer Therapeutics Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。